ANDA 83158, held by Hospira. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 83158 (Lidocaine Hydrochloride, Lidocaine Hydrochloride 0.2% In Dextrose 5%, Lidocaine Hydrochloride 0.4% In Dextrose 5%), held by Hospira, was first approved by FDA on Oct 31, 1972, with 27 approved supplements and 0 published complete response letters.
Lidocaine hydrochloride injection administered intravenously or intramuscularly, is specifically indicated in the acute management of ventricular arrhythmias such as those occurring in relation to acute myocardial infarction, or during cardiac manipulation, such as cardiac surgery.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 31, 1972 | Original application | Approved | None posted |
| Lidocaine Hydrochloride1% · injectable;injection | Lidocaine Hydrochloride | DiscontinuedReference drug |
| Lidocaine Hydrochloride2% · injectable;injection | Lidocaine Hydrochloride | DiscontinuedReference drug |
| Lidocaine Hydrochloride20% · injectable;injection | Lidocaine Hydrochloride | Discontinued |
| Lidocaine Hydrochloride 0.2% In Dextrose 5%200MG/100ML · injectable;injection | Lidocaine Hydrochloride | Discontinued |
| Lidocaine Hydrochloride 0.4% In Dextrose 5%400MG/100ML · injectable;injection | Lidocaine Hydrochloride | Discontinued |
| Apr 10, 2026 | Supplement 115Labeling · Standard review | Approved | None posted |
| Jun 14, 2021 | Supplement 122Manufacturing | Approved | None posted |
| Dec 3, 2002 | Supplement 96Manufacturing | Approved | None posted |
| Oct 25, 2002 | Supplement 95Manufacturing | Approved | None posted |
| Jan 2, 2002 | Supplement 94Labeling | Approved | None posted |
| Oct 3, 1996 | Supplement 92Manufacturing | Approved | None posted |
| Sep 20, 1996 | Supplement 88Manufacturing | Approved | None posted |
| Nov 16, 1995 | Supplement 89Manufacturing | Approved | None posted |
| Nov 2, 1995 | Supplement 90Manufacturing | Approved | None posted |
| Oct 20, 1994 | Supplement 87Labeling | Approved | None posted |
| Jun 20, 1994 | Supplement 86Manufacturing | Approved | None posted |
| Jul 23, 1991 | Supplement 85Labeling | Approved | None posted |
| Sep 20, 1990 | Supplement 84Labeling | Approved | None posted |
| Sep 20, 1990 | Supplement 81Labeling | Approved | None posted |
| Apr 18, 1990 | Supplement 80Labeling | Approved | None posted |
| Aug 4, 1989 | Supplement 83Labeling | Approved | None posted |
| Aug 5, 1986 | Supplement 78Manufacturing | Approved | None posted |
| Feb 18, 1986 | Supplement 76Manufacturing | Approved | None posted |
| Aug 13, 1985 | Supplement 75Manufacturing | Approved | None posted |
| Oct 26, 1984 | Supplement 74Manufacturing | Approved | None posted |
| May 16, 1983 | Supplement 67Manufacturing | Approved | None posted |
| Sep 23, 1982 | Supplement 65Manufacturing | Approved | None posted |
| Jul 19, 1982 | Supplement 64Manufacturing | Approved | None posted |
| Jun 23, 1982 | Supplement 63Manufacturing | Approved | None posted |
| Jun 23, 1982 | Supplement 61Manufacturing | Approved | None posted |
| Jun 23, 1982 | Supplement 60Manufacturing | Approved | None posted |
| Jun 23, 1982 | Supplement 57Manufacturing | Approved | None posted |
| Oct 31, 1972 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters